Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06683118

Registration Trial of the Drug-coated Balloon for the Symptomatic Cerebral Atherosclerotic Stenosis

The purpose of the trail is to determine whether DCB is superior to conventional balloon in treating cerebral atherosclerotic stenosis

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tiantan Hospital Affiliated of Peking University, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Incsion Criteria:

  • Age 18 to 80 years old at informed consent signing.
  • Symptomatic atherosclerotic stenosis of cerebrovascular arteries with ≥70% stenosis.
  • Medication ineffective.
  • modified Rankin Scale(mRS) score≤2.
  • The subject or guardian is able to understand the purpose of the study, is willing to participate and has given written informed consent.

Exclusion criteria

  • History of acute ischemic stroke within 2 weeks;
  • Stenosis due to non-atherosclerotic lesions such as arterial dissection, Moya-Moya disease and vasculitic disease;
  • Target vessels complete occlusion or with thrombus in target vessels;
  • Target vessel with severe calcification or distortion that making interventional device is difficult to place;
  • History of stenting in the target artery;
  • Target vessel restenosis following stenting or balloon angioplasty;
  • Combined with other lesion with ≥70% stenosis in target vessel.
  • Residual stenosis ≥50% or vessel dissection with obvious blood flow restriction occurs after predilation.
  • Combined with intracranial tumour, arteriovenous malformation or aneurysm of the target vessel.
  • History of intracranial hemorrhage within 90days.
  • Presence of severe systemic diseases that cannot tolerate surgery, such as severe liver and kidney dysfunction;
  • Contraindication to the use of anticoagulants and antiplatelet agents, such as sllergy to anticoagulants and antiplatelet agents, active bleeding or coagulation disorders;
  • Allergic to contrast agents or rapamycin;
  • Pregnant or lactating women;
  • Participating or intending to participate in any other drug/device clinical trials;
  • Life expectancy <1 year;
  • Any other conditions that the investigator deems the patient unsuitable for enrollment.

Treatment and study plan

Rapamycin neurovascular Balloon Catheter

Device

Drug-coated balloon for the symptomatic cerebral atherosclerotic stenosis

Conventional Balloon

Device

Conventional Balloon for the symptomatic cerebral atherosclerotic stenosis

Primary outcomes

  1. Target lesion restenosis rate at 6 month postoperative

    Time frame: 180±30days

    The primary endpoint was the restenosis rate at 6 month postoperatively. Restenosis was defined as ≥50% measured stenosis of the target lesion by imaging according to WASID method.

Secondary outcomes

  1. Technical succeed rate

    Time frame: Intraoperation

    defined as smooth delivery of the device to the target lesion and successful dilatation, unloading, and retraction

  2. Target vascular-related stroke or death at 30 days postoperatively

    Time frame: 30±7days

  3. Any stroke or death at 30 days postoperatively

    Time frame: 30±7days

  4. Target vascular-related stroke or death at 6 month postoperatively

    Time frame: 180±30days

  5. Any stroke or death at 6 month postoperatively

    Time frame: 180±30days

  6. Target vascular-related stroke or death at 12 month postoperatively

    Time frame: 360±60days

  7. Any stroke or death at 12 month postoperatively

    Time frame: 360±60days

Sponsors and collaborators

Lead sponsor

MicroPort NeuroTech Co., Ltd.

Industry

Registry information

Official study title

A PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SUPERIORITY, RANDOMIZED, CONTROLLED REGISTRATION TRIAL OF THE RAPAMYCIN NEUROVASCULAR BALLOON CATHETER FOR THE TREATMENT OF SYMPTOMATIC CEREBRAL ATHEROSCLEROTIC STENOSIS

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Nov 12, 2024
Registry last updated
Nov 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.